Barclay, K., Carruthers, R., Traboulsee, A., Bass, A. D., LaGanke, C., Bertolotto, A. ... Wijmeersch, B. V. (2019). Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology, 10.. doi: 10.3389/fneur.2019.00253
Barclay, Krista, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology, vol. 10, 2019. https://doi.org/10.3389/fneur.2019.00253
Barclay, Krista, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology 10 (2019). https://doi.org/10.3389/fneur.2019.00253
Barclay, K., et al. (2019) 'Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings', Frontiers in Neurology, 10. doi: 10.3389/fneur.2019.00253
Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, i sur.. Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology [Internet]. 22.03.2019. [pristupljeno 07.09.2024.];10. doi: 10.3389/fneur.2019.00253
K. Barclay, et al., "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings", Frontiers in Neurology, vol. 10, Ožujak 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:548907. [Citirano: 07.09.2024.]